1. A Review on Commercial Oligonucleotide Drug Products.
- Author
-
Vinjamuri, Bhavani Prasad, Pan, Jiayi, and Peng, Paul
- Subjects
- *
RNA , *PRODUCT attributes , *OLIGONUCLEOTIDES , *APTAMERS , *DRUGS - Abstract
• Provided comprehensive overview of all the 20 oligonucleotide drug products commercially approved till March 2024. • Focused on nature, formulation composition, presentation, primary packaging, in-use stability, and long-term stability. • Proposed generalized formulations that could be used as a starting point in early phase development of an oligonucleotide molecule recognizing that safety and efficacy must be established by controlled preclinical and clinical investigations. Oligonucleotide drug products commercially approved in the US and the EU are reviewed. A total of 20 products that includes 1 aptamer, 12 antisense oligonucleotides (ASOs), 6 small interfering ribonucleic acids (siRNAs), and 1 mixture of single-stranded and double-stranded polydeoxyribonucleotides have been identified. A typical oligonucleotide formulation is composed of an oligonucleotide with buffering agent(s), pH adjusting agents, and a tonicity adjusting agent. All the products are presented as 2.1 – 200 mg/mL solutions at pH between 6 and 8.7. Majority of the products are approved for intravenous (IV) and subcutaneous (SC) routes, with two for intravitreal (IVT), two for intrathecal (IT), and one for intramuscular (IM) routes. The primary packaging includes vials and prefilled syringes (PFS). Products approved for IV and IT administration routes and requiring >1.5 mL dose volumes are supplied in vials, while those approved for SC, IM, and IVT and requiring ≤1.5 mL dose volume are supplied in PFS. Based on the compiled dataset, we propose a generalized starting point for an oligonucleotide formulation during early phase development for IV, SC, and IT administration routes. Overall, we believe this harmonized evaluation and understanding of various oligonucleotide drug product attributes will help derive platform generalizations and allows for accelerated early phase development for first-in-human studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF